Zobrazeno 1 - 10
of 81
pro vyhledávání: '"Acyl glucuronidation"'
Autor:
Mark P. Grillo
Publikováno v:
Transporters and Drug-Metabolizing Enzymes in Drug Toxicity
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7de6b2ee3dd362ab9e2042d5906c1de8
https://doi.org/10.1002/9781119171003.ch6
https://doi.org/10.1002/9781119171003.ch6
Autor:
Yurie Katsube, Shin-ya Morita, Daiki Hira, Tetsuya Minegaki, Yoshito Ikeda, Tomohiro Terada, Masayuki Tsujimoto, Kohshi Nishiguchi, Hiroyoshi Koide
Publikováno v:
Drug Metabolism and Disposition. 49:289-297
Growing evidence suggests that certain glucuronides function as potent inhibitors of cytochrome P450 (CYP) 2C8. We previously reported the possibility of drug-drug interactions between candesartan cilexetil and paclitaxel. In this study, we evaluated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e706ea4c4244c04abf5b7f4eccf8e7e
https://doi.org/10.1124/dmd.120.000126
https://doi.org/10.1124/dmd.120.000126
Autor:
Sudheer Bobba, Edna F. Choo, Wei Wang, Jingwei Cai, Teresa Mulder, S. Cyrus Khojasteh, Donglu Zhang, Chenghong Zhang, Jessica M. Grandner, Kevin M. Johnson
Publikováno v:
Drug Metabolism and Disposition. 48:819-829
Following oral administration of [14C]GDC-0810, an α,β-unsaturated carboxylic acid, to monkeys, unchanged parent and its acyl glucuronide metabolite, M6, were the major circulating drug-related components. In addition, greater than 50% of circulati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cc0103a353b6322d20622e76a90df1e
https://doi.org/10.1124/dmd.120.000096
https://doi.org/10.1124/dmd.120.000096
Autor:
Cindy Q. Xia, Sandeepraj Pusalkar, Yuexian Li, Karthik Venkatakrishnan, Suresh K. Balani, Lawrence Cohen, Xiaofei Zhou, Wen Chyi Shyu, Jun Johnny Yang, Swapan Chowdhury, Chuang Lu
Publikováno v:
Drug Metabolism and Disposition. 48:217-229
Alisertib (MLN8237) is an investigational, orally available, selective aurora A kinase inhibitor in clinical development for the treatment of solid tumors and hematologic malignancies. This metabolic profiling analysis was conducted as part of a broa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::166eb285f2919cd372a7ec5c53356ca7
https://doi.org/10.1124/dmd.119.087338
https://doi.org/10.1124/dmd.119.087338
Autor:
John Litchfield, Arthur Bergman, Amit S. Kalgutkar, Karen Atkinson, David J. Kazierad, Raman Sharma
Publikováno v:
Xenobiotica. 49:1447-1457
1. The absorption, metabolism, and excretion of a single oral 450-mg dose of [14C]-(S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, was investigated in huma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06f46ce45f353310b2ce8d2e6fba99e3
https://doi.org/10.1080/00498254.2019.1581960
https://doi.org/10.1080/00498254.2019.1581960
Publikováno v:
Toxicology Letters. 272:1-7
Acyl glucuronides are important metabolites of compounds with carboxylic acid moieties and have unique properties that distinguish them from other phase 2 metabolites. In particular, in addition to being often unstable, acyl glucuronide metabolites c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::38769350dd7562351cc57efd116b81b2
https://doi.org/10.1016/j.toxlet.2017.03.003
https://doi.org/10.1016/j.toxlet.2017.03.003
Publikováno v:
Drug testing and analysisREFERENCES. 12(6)
Lumiracoxib is a selective cyclooxygenase-2 inhibitor, which has been reported to cause rare but severe liver injury. Considering that lumiracoxib has a carboxylic group in the molecule, glucuronidation to form acylglucuronide would be one of the pos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::830b5fa6bc14fab2bf11f9480ef19fa5
https://pubmed.ncbi.nlm.nih.gov/32043805
https://pubmed.ncbi.nlm.nih.gov/32043805
Publikováno v:
Xenobiotica. 47:538-546
1. The pharmacokinetics and metabolism of lumiracoxib in male C57bl/6J mice were investigated following a single oral dose of 10 mg/kg. 2. Lumiracoxib achieved peak observed concentrations in the blood of 1.26 + 0.51 μg/mL 0.5 h (0.5–1.0) post-dos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06712fafe93ae7eafcdcbb2ddc462fc1
https://doi.org/10.1080/00498254.2016.1206239
https://doi.org/10.1080/00498254.2016.1206239
Publikováno v:
Journal of Veterinary Pharmacology and Therapeutics. 40:123-129
Use of the immunosuppressant mycophenolic acid (MPA) in cats is limited because MPA elimination depends on glucuronidation, which is deficient in cats. We evaluated formation of major (phenol glucuronide) and minor (acyl glucuronide, phenol glucoside
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41f93c2985d816fc5157e13de580b70d
https://doi.org/10.1111/jvp.12338
https://doi.org/10.1111/jvp.12338
Autor:
Jiang Yiguo, Jianqing Ruan, Dandan Zhou, Hongjian Zhang, Yao Ni, Linghua Kong, Yedong Wang, Cheng Wang
Publikováno v:
Chemico-biological interactions. 310
Ursodeoxycholic acid (UDCA) is a major effective constituent of bear bile powder, which is widely used as function food in China and is documented in the Chinese pharmacopoeia as a traditional Chinese medicine. UDCA has been developed as the only acc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3565d58d8514b98559a0985ebeee269
https://pubmed.ncbi.nlm.nih.gov/31299240
https://pubmed.ncbi.nlm.nih.gov/31299240